The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
108 / 175
Overall Ranking
390 / 4720
Industry
Pharmaceuticals
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. It holds a majority equity interest in LipoMedix Pharmaceuticals Ltd. (a clinical-stage pharmaceutical company), Barer Institute Inc. (a preclinical cancer metabolism research operation), and a majority interest in Cornerstone Pharmaceuticals, Inc. (a cancer metabolism-based therapeutics company). It holds a majority interest in Rafael Medical Devices, LLC., an orthopedic-focused medical device company, and a majority interest in Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their cannabis offerings enabling them to bring to market predictable versions by utilizing Day Three's pharmaceutical-grade technology and innovation like Unlokt. Its investments include Cyclo Therapeutics Inc. (developing Trappsol Cyclo). It holds a portion of a commercial building in Israel.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.37% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 637.00K.
Fairly Valued
The company’s latest PE is -1.59, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 21.63M shares, increasing 37.72% quarter-over-quarter.
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. It holds a majority equity interest in LipoMedix Pharmaceuticals Ltd. (a clinical-stage pharmaceutical company), Barer Institute Inc. (a preclinical cancer metabolism research operation), and a majority interest in Cornerstone Pharmaceuticals, Inc. (a cancer metabolism-based therapeutics company). It holds a majority interest in Rafael Medical Devices, LLC., an orthopedic-focused medical device company, and a majority interest in Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their cannabis offerings enabling them to bring to market predictable versions by utilizing Day Three's pharmaceutical-grade technology and innovation like Unlokt. Its investments include Cyclo Therapeutics Inc. (developing Trappsol Cyclo). It holds a portion of a commercial building in Israel.